-
公开(公告)号:EP3999043A1
公开(公告)日:2022-05-25
申请号:EP20844387.9
申请日:2020-07-17
申请人: SPI Pharma, INC.
发明人: WILSON, Brian , MACLEOD, Graeme
-
公开(公告)号:EP3999032A1
公开(公告)日:2022-05-25
申请号:EP20840033.3
申请日:2020-07-15
申请人: Donaghys Limited
发明人: YERITSYAN, Karen
IPC分类号: A61K9/08 , A61K9/10 , A61K47/44 , A61K47/10 , A61K47/06 , A61K47/08 , A61K47/14 , A61K47/26 , A61K47/20 , A61K31/714 , A61K31/429 , A61K31/7048 , A61K31/4164 , A61K31/5415 , A61K33/04 , A61P33/00
-
公开(公告)号:EP3996682A1
公开(公告)日:2022-05-18
申请号:EP20735633.8
申请日:2020-07-08
-
74.
公开(公告)号:EP3988079A1
公开(公告)日:2022-04-27
申请号:EP20826882.1
申请日:2020-06-22
申请人: Activon Co., Ltd.
发明人: CHO, Youn Ki , PARK, Byung Gyu , CHO, Myung Chan , CHO, Se Hee , JUNG, Sung Won
摘要: Provided are a preservative for externally-applied dermal preparations including glyceryl undecylenate, glyceryl caprylate, and a glycol compound having 4 or 5 carbon atoms, and a cosmetic composition and a pharmaceutical composition, each including the same. A preservative for externally-applied dermal preparations according to one aspect may stably maintain a liquid state under room temperature and refrigerated conditions and may exhibit excellent antimicrobial effect even after formulation.
-
公开(公告)号:EP3980043A1
公开(公告)日:2022-04-13
申请号:EP20819557.8
申请日:2020-06-05
申请人: Hexo Operations Inc.
IPC分类号: A61K36/185 , A61K31/05 , A61K31/352 , A61K47/10 , A61K47/14 , A61K9/00 , A61K9/10 , A61K9/107 , C07C39/23 , C07D311/80
-
公开(公告)号:EP3964200A1
公开(公告)日:2022-03-09
申请号:EP21202298.2
申请日:2016-12-10
申请人: ModernaTX, Inc.
发明人: BESIN, Gilles , HOGE, Stephen , SENN, Joseph , BENENATO, Kerry , SABNIS, Staci
摘要: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in viva including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in viva.
-
公开(公告)号:EP3960202A1
公开(公告)日:2022-03-02
申请号:EP20795411.6
申请日:2020-04-22
发明人: URAI Soichiro , NAGAO Koji , YOKOO Yoshiaki
IPC分类号: A61K45/00 , A61P3/04 , A61P3/10 , A61P43/00 , A61K9/10 , A23L33/10 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/34 , A23L2/52 , A61K38/00 , A61K38/04 , A61K31/19 , A61K31/198 , A61K31/215 , A61K31/7004 , A61K31/7016
摘要: The development of a superior GLP-1 secretion-promoting component is expected. The present invention provides a GLP-1 secretion-promoting composition comprising a GLP-1 secretion-promoting component and an emulsified particle that contains an oil-in-water emulsifying agent.
-
公开(公告)号:EP3740196B1
公开(公告)日:2022-02-23
申请号:EP19700424.5
申请日:2019-01-15
-
公开(公告)号:EP3954363A1
公开(公告)日:2022-02-16
申请号:EP21180655.9
申请日:2014-02-27
发明人: BATT, Laurie Robert , WIN, Su , DAVIES, Keryn
IPC分类号: A61K9/08 , A61K47/06 , A61K47/08 , A61K47/10 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K31/135 , A61K31/166 , A61K31/365 , A61K31/429 , A61K31/495 , A61K31/506 , A61K31/573 , A61K31/7048
摘要: The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester solvent and/or a tripropylene glycol alkyl ether. The composition can be used to deliver a range of actives, such as anthelmintics. The present invention provides a platform composition and can be used to deliver a wide variety of active ingredients and combinations thereof transdermally to mammals.
-
80.
公开(公告)号:EP3950071A1
公开(公告)日:2022-02-09
申请号:EP20782831.0
申请日:2020-03-27
发明人: KAWAMURA, Daichi , MATSUMOTO, Izumi , AKAMINE, Takayuki , TONE, Saori , NAKAMURA, Yuuta , LI, Yan , OKAMOTO, Naoki
IPC分类号: A61Q19/00 , A61K9/06 , A61K9/50 , A61K9/70 , A61L15/20 , A61L15/44 , A61L26/00 , A61K8/11 , A61K8/37 , A61K8/42 , A61K47/14 , A61K47/18 , A61K47/26 , A61K31/53
摘要: Provided is a core-shell structure that can achieve both improvement in transdermal absorption of an active ingredient and reduction in skin irritation at a high level. A core-shell structure 10 includes: a core portion 11 containing an active ingredient, the core portion being solid; and a shell portion 12 containing both a first surfactant having a melting point of less than 35°C and a second surfactant having a melting point of 35°C or more, the first surfactant and the second surfactant each having an HLB value of 4 to 14, the first surfactant and the second surfactant each containing at least one selected from the group consisting of sorbitan fatty acid esters, glycerin fatty acid esters, propylene glycol fatty acid esters, and fatty acid alkanolamides.
-
-
-
-
-
-
-
-
-